

RECORDATI: 2026 CORPORATE EVENTS' CALENDAR

Milan, 28th January 2026 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2026:

17th February	Board of Directors' meeting to approve the 2025 preliminary consolidated results.
18 th February	<i>At 2.00 pm (CET): conference call on the 2025 preliminary consolidated results.</i>
19th March	Board of Directors' meeting to approve the 2025 consolidated financial statements and the draft of Recordati S.p.A.'s 2025 financial statements.
29th April	Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2025 financial statements and to appoint Board of Statutory Auditors.
12th May	Board of Directors' meeting to approve the 2026 first quarter results, as additional voluntary financial reporting.
13 th May	<i>At 2.00 pm (CEST): conference call on the 2026 first quarter results.</i>
28th July	Board of Directors' meeting to approve the 2026 half-yearly report.
29 th July	<i>At 2.00 pm (CEST): conference call on the results for the first half of 2026.</i>
10th November	Board of Directors' meeting to approve the 2026 first nine months' results, as additional voluntary financial reporting.
11 th November	<i>At 2.00 pm (CET): conference call on the 2026 first nine months' results.</i>

Recordati S.p.A. announces that the payment of the balance of the 2025 financial year dividend is planned for 20th May 2026, on each outstanding share at 18th May 2026 (ex-dividend rate) and record date 19th May 2026, while the payment of the interim dividend for the 2026 financial year is planned for 25th November 2026, on each outstanding share at 23rd November 2026 (ex-dividend rate) and record date at 24th November 2026.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar as well as any further dedicated meetings/conference calls with the financial community will be promptly notified to the market and will be made available in the company website.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office
Via Matteo Civitali, 1
20148 Milano, Italy
Tel. +39 02 487871
Fax +39 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l

Recordati is an international pharmaceutical Group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialisation and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,580 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

Investor Relations

Eugenia Litz
+44 7824 394 750
Eugenia.Litz@recordati.com

Gianluca Saletta
+39 348 979 4876
saletta.g@recordati.it

Media Relations

Laura Conti
conti.l@recordati.it

Rebecca Kerr
rebecca.kerr@recordati.com

This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast for a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the activities of the Recordati Group, and, as such, it is not intended as a medical scientific indication or recommendation, or as advertising.